Genentech Seeks $122 Million in Unpaid Royalties from Biogen in Federal Court Dispute

In a legal confrontation unfolding in a California federal court, Genentech Inc. asserts that Biogen MA Inc. owes $122 million in royalties. The dispute centers on Biogen’s manufacturing of a multiple sclerosis drug before the expiration of Genentech’s patent in December 2018. Genentech argues that royalties are due for the drug supplies produced under the patent’s protection. In response, Biogen insists that the licensing agreement between the companies does not mandate royalty payments for sales of the drug that occurred after the patent expired. For further information on this matter, detailed coverage is available on Law360.